Characterization and subcellular distribution of somatogenic receptor in rat liver

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma

Background/Aims

Growth hormone (GH) is the main regulator of somatic growth, metabolism, and gender dimorphism in the liver. GH receptor (GHR) signaling in cancer is derived from a large body of evidence, although the GHR signaling pathway involved in the prognosis of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related HCC, remains unclear. We aimed to explore the expression of GHR and analyze its association with clinicopathologic features and prognosis of patients with chronic hepatitis C and HCC.

Methods

The expression of GHR mRNA was investigated by quantitative real-time polymerase chain reaction in paired tumors and adjacent non-tumorous (ANT) liver tissues of 200 patients with chronic hepatitis C and HCC. Western blotting and immunofluorescence assays using the HCV-infected Huh7.5.1 cell model was performed.

Results

GHR mRNA was significantly lower in HCV-HCC tissues than in corresponding ANT liver tissues. GHR mRNA and protein levels also decreased in the HCV-infected Huh7.5.1 cell model. Notably, lower GHR expression was associated with age of >60 years (P=0.0111) and worse clinicopathologic characteristics, including alpha-fetoprotein >100 ng/mL (P=0.0403), cirrhosis (P=0.0075), vascular invasion (P=0.0052), pathological stage II–IV (P=0.0002), and albumin ≤4.0 g/dL (P=0.0055), which were linked with poor prognosis of HCC. Most importantly, the high incidence of recurrence and poor survival rates in patients with a low ratio of tumor/ANT GHR (≤0.1) were observed, indicating that low expression levels of GHR had great risk for development of HCC in patients with chronic hepatitis C.

Conclusions

Our study demonstrates a significant down-regulation of GHR expression as a new unfavorable independent prognostic factor in patients with chronic hepatitis C and HCC.

Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma

The death rates of hepatocellular carcinoma (HCC) are extremely high due to the paucity of therapeutic options. Animal models and anecdotal clinical evidence indicate a potential role of hGH and hPRL in HCC. However, the prognostic relevance and the functional role of tumor expression of these hormones in human HCC are not defined. Herein, we analyzed the mRNA and protein expression of hGH and hPRL in histopathological samples of non-neoplastic liver and HCC by in situ hybridization, PCR and immunohistochemistry techniques. Increased mRNA and protein expression of both hormones was observed in HCC compared with non-neoplastic liver tissues. hGH expression was significantly associated with tumor size and tumor grade. No significant association was observed between the expression of hPRL and any histopathological features. Amplification of both hGH and hPRL genes in HCC was observed when compared to non-neoplastic tissue. Expression of both hGH and hPRL was associated with worse relapse-free and overall survival in HCC patients. In vitro and in vivo functional assays performed with HCC cell lines demonstrated that autocrine expression of hGH or hPRL in HCC cells increased STAT3 activation, oncogenicity and tumor growth while functional antagonism with hGH-G120R significantly reduced these parameters. Hence, tumor expression of hGH/hPRL is associated with a worse survival outcome for patients with HCC and hGH/hPRL function as autocrine/paracrine promoters of HCC progression.

Protective effects of recombinant human growth hormone on cirrhotic rats

AIM: To investigate the effects and molecular mechanisms of recombinant human growth hormone (rhGH) on protecting liver function and alleviating portal hypertension of liver cirrhotic rats.

METHODS: Liver cirrhosis of male Sprague-Dawley rats was induced by administration of thioacetamide. The rats with or without liver cirrhosis were randomly divided into four groups. Group A consisted of the normal rats was treated with normal saline (NS), group B consisted of the normal rats was treated with rhGH, group C consisted of cirrhotic rats was treated with NS, and group D consisted of cirrhotic rats was treated with rhGH. The rats of different groups were subcutaneously injected with 0.5 mL of NS or 333 ng/kg of rhGH daily for 7 d. After treatments, the following parameters were examined, including GH-binding capacity (R_T) by ¹²⁵I-hGH binding, growth hormone receptor mRNA(GHR mRNA) expression by RT-PCR, relative content of collagen (RCC) by histomorphomertry, and level of malon-dialdehyde (MDA) and superoxide dismutase (SOD) in liver tissue by thiobarbituric acid reaction and pyrogallic acid self-oxidation, respectively. Serum albumin (ALB), alanine transaminase (ALT) and portal vein pressure (PVP) were also examined.

RESULTS: rhGH up-regulated both the GH-binding capacity (R_T) and the expression of GHR mRNA in vivo. R_T in group A (72 ± 12 fmol/mg protein) was significantly higher than that in group C (31 ± 4 fmol/mg protein) (P < 0.05). R_T in group B (80 ± 9 fmol/mg protein) increased markedly compared to group A (P < 0.05). R_T in group D (40 ± 7 fmol/mg protein) raised remarkably compared with group C (P < 0.05), but less than that in group A, and there was no significant GH binding affinity contrast (Kd) change. The GHR mRNA level (iOD, pixel) in group A (29 ± 3) was significantly higher than that in group C (23 ± 3) (P < 0.05). GHR mRNA levels were significantly raised in group B (56 ± 4) and group D (42 ± 8) compared with groups A and C (29 ± 3 and 23 ± 3, respectively) (P < 0.05). Compared with the normal liver, MDA level was higher and SOD level was lower in cirrhotic livers. After rhGH treatment, MDA level was significantly declined to 12.0 ± 2.2 nmol/mg protein and SOD was raised to 1029 ± 76 U/mg protein in group D (P < 0.05). ALB levels in groups B and D (42 ± 7 g/L and 37 ± 7 g/L, respectively) were significantly raised compared with those in groups A and C (35 ± 5 g/L and 29 ± 4 g/L, respectively) (P < 0.05). ALT level was markedly lower in group D (69 ± 7 U/L) compared to group C (89 ± 15 U/L) (P < 0.05), and close to group A (61 ± 10 U/L). RCC in group C (22.30% ± 3.86%) was significantly higher than that in group A (1.14% ± 0.21%) and group D (14.70% ± 2.07%) (P < 0.05). In addition, rhGH markedly alleviated portal hypertension in liver cirrhotic rats (group D vs C, 9.3 ± 1.5 cmH₂O vs 14.4 ± 2.0 cmH₂O) (P < 0.05).

CONCLUSION: Pharmacological doses of rhGH can increase R_T and GHR mRNA expression, ameliorate liver functions, repress fibrosis and decline portal hypertension, suggesting it has potentially clinical usage as a hepatotropic factor.

Effects of rGH and G118RrGH on the induction of CYP2C12 and IGF-I in primary rat hepatocytes

We have investigated the induction of the CYP2C12 and IGF-I genes by rGH and a "binding site 2 mutant", G118RrGH, in primary hepatocytes derived from male and female rats. Both the basal and the induced levels of CYP2C12, but not of IGF-I, were markedly lower in male derived than in female derived hepatocytes. A lower degree of receptor occupancy appears needed to elicit the CYP2C12 than the IGF-I response in cells obtained from both gender. At 7h of GH exposure high doses of rGH caused a bell-shaped induction of IGF-1 and a plateau was reached for CYP2C12 in female derived cells. G118RrGH did not antagonize the rGH effect; in contrast G118RrGH had an agonistic effect on CYP2C12 induction in female derived cells that in dose-response experiments was bell-shaped. The difficulty in achieving bell-shaped dose-response curves with rGH, together with the lack of an antagonistic effect of G118RrGH, suggests that both binding sites of rGH have similar affinity for the rGHR. The agonistic and bell-shaped dose-related effect of G118RrGH on CYP2C12 expression indicates that G118RrGH interacts with two receptors. The results could also imply that rGH, via its site 2, can interact with other receptor molecules than rGHR.

Expression of growth hormone receptor and its mRNA in hepatic cirrhosis

AIM: To investigate the expression of growth hormone receptor (GHR) and mRNA of GHR in cirrhotic livers of rats with the intension to find the basis for application of recombinant human growth hormone (rhGH) to patients with liver cirrhosis.

METHODS: Hepatic cirrhosis was induced in Sprague-Dawley rats by administration of thioacetamide intraperitoneally for 9-12 weeks. Collagenase IV was perfused in situ for isolation of hepatocytes. The expression of GHR and its mRNA in cirrhotic livers was studied with radio-ligand binding assay, RT-PCR and digital image analysis.

RESULTS: One class of specific growth hormone-binding site, GHR, was detected in hepatocytes and hepatic tissue of cirrhotic livers. The binding capacity of GHR (R_T, fmol/mg protein) in rat cirrhotic liver tissue (30.8 ± 1.9) was significantly lower than that in normal control (74.9 ± 3.9) at the time point of the ninth week after initiation of induction of cirrhosis (n = 10, P < 0.05), and it decreased gradually along with the accumulation of collagen in the process of formation and development of liver cirrhosis (P < 0.05). The number of binding sites (× 10⁴/cell) of GHR on rat cirrhotic hepatocytes (0.86 ± 0.16) was significantly lower than that (1.28 ± 0.24) in control (n = 10, P < 0.05). The binding affinity of GHR among liver tissue, hepatocytes of various groups had no significant difference (P > 0.05). The expression of GHR mRNA (riOD, pixel) in rat cirrhotic hepatic tissues (23.3 ± 3.1) was also significantly lower than that (29.3 ± 3.4) in normal control (n = 10, P < 0.05).

CONCLUSION: The growth hormone receptor was expressed in a reduced level in liver tissue of cirrhotic rats, and lesser expression of growth hormone receptors was found in a later stage of cirrhosis. The reduced expression of growth hormone receptor was partly due to its decreased expression on cirrhotic hepatocytes and the reduced expression of its mRNA in cirrhotic liver tissue.

Internalization of the chicken growth hormone receptor complex and its effect on biological functions

In the chicken, as in mammals, GH is a pleiotropic cytokine that plays a central role in growth differentiation and metabolism by altering gene expression in target cells. In the growing and adult chicken it stimulates gene expression of IGF-I and inhibits gene transcription of the type III deiodinating enzyme (D3) and by doing so also increases T(3) concentrations. GH binding to its receptor leads to internalization of the GH-GHR complex to the Golgi apparatus. This process is linked to the episodic release pattern of GH during growth. At the same time, a sharp decline of the expression of cGHR occurs at hatching. An in vitro study using a COS-7 cell line transfected with the cDNA of the chicken GHR, revealed that GHR immunofluorescence was found in the perinuclear region and on the plasma membrane. Following GH-induced internalization, GH and GHR were colocalized in endocytic and later in large lysosomal vesicles. Neither receptor nor ligand was transferred to the nucleus as confirmed by confocal laser microscopy. The JAK/STAT pathway however, as reported for mammalian GH receptors, mediated GH-induced gene transcription in chickens.

Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas

The liver is an essential target tissue for growth hormone (GH) and prolactin (PRL). The aim of this study was to determine the in situ expression of growth hormone receptor (GHR) and prolactin receptor (PRLR) in hepatocellular carcinomas and to compare the results with normal liver. For this purpose, in situ hybridization (ISH) and immunohistochemical techniques were performed and several tests were conducted to validate the results. By radioactive ISH, all the hepatocellular carcinomas studied showed labeling for GHR and PRLR mRNAs. Relative expression levels, determined by computer-assisted microdensity, were higher in hepatocellular carcinomas than in normal liver. Immunohistochemistry led us to confirm the constant expression of both receptor proteins in hepatocellular carcinomas and normal liver and to demonstrate their localization not only in the cytoplasm but also in the nucleus. These results confirm that the liver is a major GH and PRL target tissue and suggest that in hepatocellular carcinomas the proliferative effects of these hormones may be increased by a higher expression of their receptors.

Responsiveness of an SV40-immortalized hepatocyte cell line to growth hormone

The response of an SV40-immortalized hepatocyte cell line (CWSV-1) derived from adult male rat hepatocytes to human growth hormone (hGH) was investigated. CWSV-1 cells, which have been characterized extensively, retain certain differentiated functions of normal liver (Woodworth and Isom, Mol Cell Biol 7: 3740-3748, 1987). This cell line consists of tightly associated polygonal, mononucleated cells that grow as monolayers. These cells showed no significant morphological changes with the addition of hGH. Northern blot analysis showed that continuous treatment of the CWSV-1 cells with hGH induced the expression of insulin-like growth factor I (IGF-I) and 5 alpha-reductase RNAs. In addition, continuous exposure to hGH resulted in the induction of expression of the growth hormone receptor/growth hormone binding protein (GHR/GHBP) genes. This study indicates that the CWSV-1 cells may serve as a valuable in vitro model system for studying the signaling pathway of GH.

Increased expression of and sensitivity to transforming growth factor-alpha: a promotive role during rat liver carcinogenesis

The influence of the tumor promoter 2-acetylaminofluorene (2-AAF) on cell proliferation and on the epidermal growth factor receptor (EGFR) system was assessed in normal and nodular rat livers. DNA replication in vivo was inhibited below the detection level after 8d of dietary 2-AAF treatment of previously unexposed rats. The 2-AAF-induced growth inhibition was accompanied by downregulation of the number of epidermal growth factor (EGF)-binding sites and decreased levels of EGFR transcripts, whereas no changes in the transforming growth factor-alpha (TGF-alpha) mRNA levels were observed. The persistent liver nodules generated by intermittent 2-AAF-feeding had a 30- to 35-fold higher replicating cell fraction than normal liver. Treatment with 2-AAF in vivo reduced the replicating cell fraction to one third in nodules after 14 d of 2-AAF treatment. The initial EGFR mRNA levels and number of EGF binding sites in nodules before 2-AAF administration was about 605 that of control livers and was slightly reduced by 2-AAF feeding. The levels of EGFR mRNA after 14 d of 2-AAF feeding were thus similar in the nodules and in the 2-AAF-treated control livers, whereas the fraction of proliferating cells in nodules after the 2-AAF treatment was much larger than in normal liver. The TGF-alpha mRNA level in the nodules was found to be 1.4-fold and in malignant hepatomas 1.7-fold the level in normal liver. Primary hepatocytes isolated from control livers were four to five times more sensitive to replicative stimulation with EGF than with TGF-alpha, whereas nodular cells responded at lower concentrations than control cells and equally well to both EGF and TGF-alpha. We conclude that the decreased amounts of EGFR in the nodular cells with respect to proliferative stimulation could be more than compensated for by elevated synthesis of TGF-alpha combined with an increased TGF-alpha sensitivity. Collectively, these changes implicate TGF-alpha in sustaining cell proliferation during chemically induced rat liver carcinogenesis.

Regulation of the growth hormone (GH) receptor and GH-binding protein by GH pulsatility

Growth hormone (GH) secretion is pulsatile in man and every other mammalian species that has been studied. The magnitude of pulses, their frequency, and their regularity vary. The receptor, on its part, undergoes cycles of internalization and recycling that are in synchrony with the frequency of GH pulses. This sequence of events has been shown to be advantageous to growth. It is suggested that changes in GH secretion dynamics secondarily lead to most of the changes in GH receptor abundance and GH-binding protein (GH-BP) abundance. Across a wide scope of comparative studies, ontogenesis data, experimental systems, physiologic conditions, nutritional states, and disease situations, the pulsatility of serum GH is negatively correlated with cell membrane GH receptors and serum levels of GH-BP. It is suggested that these conditions regulate primarily the pattern of GH pulsatility, which in turn regulates the GH receptor/GH-BP, and thereby exert the specific effects on target cells to promote or suppress growth or to express distinct metabolic actions.

The role and mechanism of growth hormone in the regulation of sexually dimorphic P450 enzymes in rat liver

The determination of sexually dimorphic hepatic steroid metabolism in rat liver has been shown to involve growth hormone. However, the mechanisms by which growth hormone controls the cytochrome P450 enzymes responsible for this dimorphic steroid metabolism is largely unknown. In this review we discuss different levels of growth hormone signal transduction, including receptor binding, signal transduction and activation of target genes by growth hormone.

Characterization of putative growth hormone receptors in human choroid plexus

The ability to bind iodine-labelled human growth hormone ([125I]hGH) was measured in different parts of the human brain. The choroid plexus contained the highest amount of binding sites (receptors) and was therefore selected for further studies. The binding between [125I]hGH and the receptor was saturable, of high affinity (Ka = 0.63 nM-1) and pH- as well as time-dependent. After solubilization with Triton X-100 the receptors retained their hormone-binding properties and eluted in the high molecular weight range (greater than 500,000) upon molecular sieve chromatography. Analysis by an affinity cross-linking technique indicated a hormone-binding unit of molecular weight 51,000. The molecular characteristics of the identified binding sites are discussed in comparison to those of growth hormone receptors of human and animal origin.

Pretranslational and posttranslational regulation of the EGF receptor during the prereplicative phase of liver regeneration

We studied the regulation of the epidermal growth factor receptor mRNA and the number of epidermal growth factor binding sites in subcellular compartments involved in the biosynthesis and endocytosis of the epidermal growth factor receptor during the prereplicative phase of liver regeneration. The epidermal growth factor receptor mRNA, quantified by solution hybridization, decreased after partial hepatectomy, with a nadir of about 35% 18 hr after hepatectomy. An even stronger decrease in the number of epidermal growth factor binding sites after partial hepatectomy was observed in a Golgi-enriched low-density membrane fraction, reflecting available newly synthesized epidermal growth factor receptors. It is suggested that this decrease in newly synthesized available epidermal growth factor receptors is caused primarily, but not entirely, by decreased epidermal growth factor receptor mRNA levels and the additional down-regulation of epidermal growth factor binding sites may involve posttranslational mechanisms such as intracellular occupation by transforming growth factor-alpha. The observation that the number of specific epidermal growth factor binding sites after partial hepatectomy was only moderately reduced in prelysosomal endosomes and in lysosomes, compared with the newly synthesized receptors, may indicate that a pool of receptors targeted for lysosomes exists and these receptors are regulated in a different manner than the receptor pool targeted for the cell surface. Furthermore, at least two separable endocytic subcompartments are involved in the transport of the epidermal growth factor/epidermal growth factor receptor complex in the liver.(ABSTRACT TRUNCATED AT 250 WORDS)

Regulation of epidermal growth factor receptor metabolism in gingival fibroblasts by phenytoin in vitro

Normal human gingival fibroblasts derived from five children between 8 and 12 yr of age were cultured under serum-free conditions in the presence of epidermal growth factor (EGF) either alone or in combination with 5,5-diphenylhydantoin (phenytoin; PHT). DNA-synthesis, binding of EGF to its cell-surface receptor and internalisation of EGF-receptor-ligand complexes were studied. In normal gingival fibroblasts treated solely with EGF for 48 h, DNA synthesis increased significantly, as in cells treated solely with PHT. When EGF binding data was calculated according to Scatchard, it was found that the number of EGF receptors in fibroblasts increased significantly after PHT treatment. The number of EGF-receptors in untreated gingival fibroblasts varied from 147,000 to 170,000 receptors per cell whereas in PHT-treated fibroblasts the range was from 181,000 to 280,000. The study indicates that PHT regulates EGF-receptor metabolism in human gingival fibroblasts by increasing the number of cell-surface EGF-receptors which may contribute to the alteration of gingival connective tissue observed in patients undergoing PHT medication.

Effect of phenytoin medication on the metabolism of epidermal growth factor receptor in cultured gingival fibroblasts

Human gingival fibroblasts derived from 2 patients before and 9 months after the start of phenytoin (PHT) therapy were studied with respect to the effect of epidermal growth factor (EGF) on the incorporation of 3H-thymidine into DNA, binding of EGF to its cell-surface receptor, internalization of EGF-receptor-ligand complexes and, finally, with respect to EGF receptor mRNA levels. In fibroblasts derived from the patient who developed gingival overgrowth during the PHT medication (responder) as well as in the fibroblasts derived from the patient where gingival overgrowth did not develop (non-responder), the affinity of the EGF receptor for EGF was not significantly changed. In the non-responder patient the internalization of EGF receptor ligand was decreased, whereas it was increased in the fibroblasts derived from the responder patient after PHT therapy. The steady-state level of EGF-r mRNA increased significantly (p less than 0.001) in the cultured fibroblasts derived from the non-responder but decreased (p less than 0.05) in the responder patient following PHT therapy. Ligand affinity cross-linking studies revealed one major component of EGF receptor with a molecular weight of 170 KDa in fibroblasts from the non-responder as well as from the responder. The study indicates that PHT medication results in a down-regulation of EGF receptor metabolism in fibroblasts derived from a responder patient, whereas in the non-responder patient EGF receptor metabolism is up-regulated.

Similar induction of the hepatic EGF receptor in vivo by EGF and partial hepatectomy

A 2-fold increase in the level of epidermal growth factor (EGF) receptor mRNA accompanied by a similar increase in newly synthesized ligand-binding EGF-receptors was observed 2-4 h after intraportal EGF-injections and 2-4 h after partial hepatectomy. After this initial increase, the EGF-receptor levels decreased back to control levels 6-8 h after EGF-injections and below control levels 6-8 h after partial hepatectomy. EGF was also found to influence the degradation of endocytosed [125I]-EGF 3 h after injection to a similar extent as partial hepatectomy. The similar effects of EGF and partial hepatectomy suggests that EGF or EGF-like factors may be mechanistically involved in the early "promotion" stage during the pre-replicative phase of liver regeneration. The EGF-induced effects are, however, at least not alone responsible for the replicative process.

Detection of glycosylated growth hormone-binding proteins in rat serum

Affinity cross-linking technique revealed the presence of three growth hormone-binding proteins (GHBP) in dealbuminized rat serum. The apparent molecular weights, as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, were 52,000, 44,000 and 39,000. By use of carbohydrate chain cleaving enzymes it was found that the binding proteins contain N-linked complex carbohydrate chains, representing 8000, 4000 and 5000 in apparent molecular weight, respectively. Gel permeation chromatography and sucrose density gradient centrifugation revealed a growth hormone-binding entity with Stoke's radius 94.5 A (+/- 2.8, n = 5) and an s-value of 10.8 S (+/- 0.31, n = 5). The molecular weight could be calculated to 413,000. Both for gel chromatography and sucrose density gradient experiments unlabelled growth hormone reduced the radioactive peaks from 0 to 50%. The relation of this binding entity to the GHBP's described with affinity cross-linking technique and the nature of this binding entity is at present unclear. No serum binding protein(s) for prolactin was detected by affinity cross-linking technique, gel permeation chromatography or sucrose density gradient analysis.

Decreased expression of the growth hormone receptor and growth hormone binding protein in rat liver nodules

The growth hormone receptor (GHR) and growth hormone-binding protein (GH-BP) expression were characterized in liver nodules and hepatomas from male Wistar rats. The mRNA levels of GHR and GH-BP, studied by northern blot analysis and solution hybridization, were 35-50% (in nodules) and 2-6% (in hepatomas) of the level found in liver from untreated, age-matched rats. The binding of 125I-labeled human growth hormone to a low-density membrane fraction (LDMF) containing Golgi and endosome membranes in the presence of excess ovine prolactin was 75-80% lower in nodules than in liver. When endogenous ligand was removed, the binding increased in nodules but not in liver. Affinity cross-linking experiments revealed identical specific receptor-binding protein complexes at Mr of 95,000, 55,000, and 43,000 in both nodules and liver, assuming stochiometric binding of ligand. The in vivo endocytosis of 125I-labeled bovine growth hormone correlated with the level of GH binding and was thus reduced 75-80% in nodules, compared with liver. The level of insulin-like growth factor-I (IGF-I) mRNA was reduced by 50% in nodules; however, GH administration resulted in a twofold induction of IGF-I mRNA in both nodules and liver. It is concluded that the greater proportion of occupied GHR in nodules could result from an impaired dissociation of endogenous GH, which might explain the reduced GHR mRNA expression. Furthermore the low GHR mRNA expression may reflect a de-differentiated phenotype in nodules.

Regulation of sexual differentiation in drug and steroid metabolism

Certain members of the cytochrome P-450 family are expressed at different levels in the livers of male and female rats. Although little is known of the functional significance of these sex differences, progress has been made towards the understanding of the endocrine control of hepatic sex differences in cytochrome P-450 levels. Jan-Ake Gustafsson and colleagues describe a subpopulation of hepatic sexually differentiated P-450s that is regulated by sex differences in growth hormone (GH) secretory pattern. This secretory pattern is in turn regulated by gonadal steroids. These studies demonstrate a novel action of GH and suggest that the hormonal secretory rhythm is pivotal in determination of biological effects.

Receptor-mediated endocytosis and degradation of bovine growth hormone in rat liver

Receptor-mediated endocytosis of radiolabelled bovine growth hormone (125I-bGH) via somatogenic receptors in the liver was studied following in vivo intraportal injection. At different times after injection, subcellular membrane fractions involved in binding (plasma membranes), endocytosis (endocytic vesicles) and degradation (lysosomes) of peptide hormones were isolated by sucrose density gradient centrifugation. These fractions were evaluated for the time-course accumulation of radiolabelled bGH and for the presence of internalized 125I-bGH-receptor complexes. These uptake studies indicate that after initial plasma membrane association of 125I-bGH, the ligand is transported in two successive endocytic compartments prior to arrival in lysosomes. The molecular weight of the somatogenic binders of male and female rat livers involved in internalization of 125I-bGH was determined to 95,000, 64,000, 55,000, 43,000 and 35,000, assuming a 1:1 binding of the hormone to the binder. These binders were seen in both endosomes and lysosomes, which suggests that growth hormone is transported to the lysosomes in a complex with its receptor. Binding and uptake of 125I-bGH was also compared in male and female rat livers, and endocytosis of 125I-bGH was compared to that of radiolabelled ovine prolactin (125I-oPrl). The specific uptake of 125I-bGH appeared not to be sexually differentiated in contrast to that of 125I-oPrl which showed a 35-fold higher uptake in female rat liver. Degradation of 125I-bGH was studied under in vitro binding assay conditions. A distinct 15,000 Da fragment was generated by plasma membrane, endosomal and lysosomal fractions. Based on protease inhibitor studies, a non-trypsin-like serine protease is suggested to be involved in the degradation of bGH. The 15,000 Da proteolytic fragment of GH can be affinity cross-linked to somatogenic binders of similar molecular weights as those involved in the binding of intact GH.

Lactogenic and somatogenic binding sites in intact and detergent-solubilized membrane preparations of female rat liver

The presence of lactogenic and somatogenic binding sites in intact microsomal membranes and in detergent-solubilized microsomal membrane preparations of female rat liver has been studied by affinity cross-linking-SDS/polyacrylamide-gel electrophoresis. In microsomal membrane preparations an Mr 40,000 lactogenic binder is present which is not disulphide-linked to another protein. Triton X-100 solubilization of membranes results in the appearance of three lactogenic 125I-human growth hormone (125I-hGH) binders with Mr values of 87,000, 40,000 and 35,000, and one somatogenic 125I-hGH binder with Mr 32,000. Treatment of rats with oestrogen increased the amount of lactogenic and somatogenic binding species in liver. The lactogenic binding sites are present as one entity in Triton X-100-solubilized preparations, clearly separated from the somatogenic binder as analysed by gel chromatography. Furthermore, 125I-hGH interacts with an Mr 95,000 somatogenic binder in membrane preparations to which the hormone can be cross-linked only following Triton X-100 solubilization.